Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H31NO |
| Molecular Weight | 301.4662 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CC[C@](C)(C1(C)C)[C@@](C2)(OCCN(C)C)C3=CC=CC=C3
InChI
InChIKey=QOBGWWQAMAPULA-RLLQIKCJSA-N
InChI=1S/C20H31NO/c1-18(2)17-11-12-19(18,3)20(15-17,22-14-13-21(4)5)16-9-7-6-8-10-16/h6-10,17H,11-15H2,1-5H3/t17-,19-,20+/m1/s1
| Molecular Formula | C20H31NO |
| Molecular Weight | 301.4662 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Deramciclane is camphor derivative. It is an anxiolytic agent that binds with high affinity to 5-HT2A/2C receptor. Deramciclane showed significant evidence of efficacy for the treatment of generalized anxiety disorder in adult patients. A single dose of deramciclane was rapidly absorbed with peak plasma concentrations being reached after about 3 h. Deramciclane has a half-life of around 27 h. The most commonly reported adverse event was headache. In the in vitro studies deramciclane concentration-dependently inhibited NMDA evoked spreading depression.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| 8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. | 2001 Jan |
|
| Deramciclane (Egis). | 2002 Feb |
|
| Studies of the side chain cleavage of deramciclane in rats with radiolabelled compounds. | 2002 Mar |
|
| In vitro simulation of food effect on dissolution of deramciclane film-coated tablets and correlation with in vivo data in healthy volunteers. | 2002 Mar |
|
| Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration. | 2003 |
|
| Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone. | 2003 Dec |
|
| The effect of oil as a dietary component on in vitro dissolution of an acid-labile drug. | 2003 Jul |
|
| Comparison of deramciclane to benzodiazepine agonists in behavioural activity of mice and in alcohol drinking of alcohol-preferring rats. | 2004 Apr |
|
| Pharmacokinetics of deramciclane and N-desmethylderamciclane after single and repeated oral doses in healthy volunteers. | 2004 Aug |
|
| Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics. | 2004 Feb |
|
| Influence of food on the oral bioavailability of deramciclane from film-coated tablet in healthy male volunteers. | 2004 Nov |
|
| Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study. | 2005 Dec |
|
| Biotransformation of deramciclane in primary hepatocytes of rat, mouse, rabbit, dog, and human. | 2005 Nov |
|
| Role of CYP2E1 in deramciclane metabolism. | 2005 Nov |
|
| Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats. | 2008 Jan |
|
| Deramciclane improves object recognition in rats: potential role of NMDA receptors. | 2010 Feb |
|
| Selective binding interactions of deramciclane to the genetic variants of human alpha(1)-acid glycoprotein. | 2010 Mar |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:00:38 UTC 2023
by
admin
on
Wed Jul 05 23:00:38 UTC 2023
|
| Record UNII |
O5KFK61E74
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6838
Created by
admin on Wed Jul 05 23:00:39 UTC 2023 , Edited by admin on Wed Jul 05 23:00:39 UTC 2023
|
PRIMARY | |||
|
CHEMBL2104698
Created by
admin on Wed Jul 05 23:00:39 UTC 2023 , Edited by admin on Wed Jul 05 23:00:39 UTC 2023
|
PRIMARY | |||
|
DB06512
Created by
admin on Wed Jul 05 23:00:39 UTC 2023 , Edited by admin on Wed Jul 05 23:00:39 UTC 2023
|
PRIMARY | |||
|
DTXSID10152862
Created by
admin on Wed Jul 05 23:00:39 UTC 2023 , Edited by admin on Wed Jul 05 23:00:39 UTC 2023
|
PRIMARY | |||
|
C060555
Created by
admin on Wed Jul 05 23:00:39 UTC 2023 , Edited by admin on Wed Jul 05 23:00:39 UTC 2023
|
PRIMARY | |||
|
100000083184
Created by
admin on Wed Jul 05 23:00:39 UTC 2023 , Edited by admin on Wed Jul 05 23:00:39 UTC 2023
|
PRIMARY | |||
|
C174785
Created by
admin on Wed Jul 05 23:00:39 UTC 2023 , Edited by admin on Wed Jul 05 23:00:39 UTC 2023
|
PRIMARY | |||
|
119590
Created by
admin on Wed Jul 05 23:00:39 UTC 2023 , Edited by admin on Wed Jul 05 23:00:39 UTC 2023
|
PRIMARY | |||
|
SUB06986MIG
Created by
admin on Wed Jul 05 23:00:39 UTC 2023 , Edited by admin on Wed Jul 05 23:00:39 UTC 2023
|
PRIMARY | |||
|
M4186
Created by
admin on Wed Jul 05 23:00:39 UTC 2023 , Edited by admin on Wed Jul 05 23:00:39 UTC 2023
|
PRIMARY | Merck Index | ||
|
O5KFK61E74
Created by
admin on Wed Jul 05 23:00:39 UTC 2023 , Edited by admin on Wed Jul 05 23:00:39 UTC 2023
|
PRIMARY | |||
|
120444-71-5
Created by
admin on Wed Jul 05 23:00:38 UTC 2023 , Edited by admin on Wed Jul 05 23:00:38 UTC 2023
|
PRIMARY | |||
|
DERAMCICLANE
Created by
admin on Wed Jul 05 23:00:39 UTC 2023 , Edited by admin on Wed Jul 05 23:00:39 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->ANTAGONIST | |||
|
|
TARGET->ANTAGONIST |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
